”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

How antimicrobial hydrogel can revolutionize clinical treatments

Human care:

Amferia’s innovative, flexible hydrogel can be adapted to many medical applications. One of the first products we’re developing for our antimicrobial platform is a wound care dressing.

The soft, flexible Amferia antimicrobial hydrogel, can be integrated with wound dressings of various shapes and sizes. The product we’re developing will be shelf-stable for up to eighteen months—and, when applied to wounds, will bind and kill bacteria for up to five days before dressings need to be changed.

Other potential treatments showing early promise include pre-surgery skin cleansing, spray-based products for wound care, and coatings for medical devices such as catheters and implants.

The potential market for this technology is enormous—even as antibiotics continue to be less effective against certain resistant bacterial strains.

The potential market for this technology is enormous

Amferia’s hydrogel is a flexible solution that can be potentially adapted to multiple applications where killing bacteria is critical—with the added advantage that it kills even resistant bacteria. A few examples of potential applications are listed below. Some we are already developing. Others, we’re actively seeking partners to develop with us.

Read about the science behind Amferia >

Antimicrobial hydrogel wound dressing

Wound Care:

Amferia’s first product for human care is our antimicrobial hydrogel wound dressing. Amferia is developing several dressing formats that feature our patented hydrogel, starting with a non-adhesive hydrogel dressing for acute wounds, while pipeline products cater to the numerous needs within wound care keeping the antimicrobial property intact.

When applied to a wound as a solid wound dressing pad, Amferia’s antimicrobial hydrogel can bind and kill 99.9% bacteria, providing an effective, clean environment for wound recovery.  

Amferia’s proprietary hydrogel acts as the contact layer to the wound where by it provides the intended effect of binding and killing bacteria while providing a moist environment conducive for wound healing.

Today, Amferia has ongoing clinical investigations in Europe and we are seeking CE marking and FDA 510(k) clearance on this product.

Antibacterial patches prior to surgery

Pre-surgery:

Another potential application of Amferia hydrogel comes in the form of a patch that can clear the skin of bacteria before a surgical procedure. A recent study we conducted on human skin demonstrated that Amferia hydrogel kills upto 99.99% bacteria on skin surface within the first three hours.

A protective patch that can be adhered to the incision site prior to surgery, eradicating skin flora hence providing a bacteria free site of surgery. In emergency wards, where patients may be waiting in a non-sterile environment prior to surgery, a bacteria-killing patch can reduce complications and potentially save lives.

Sprays applied directly on wounds or skin

Antibacterial sprays:

The flexible nature of our hydrogel platform allows us to apply the patented bacteria-killing hydrogel in many forms—like a spray. Small particles of the antimicrobial hydrogel, can be dispersed through an aerosol to cover broader areas of the skin and wounds. A pipeline product being developed at Amferia is a spray that can be applied directly to wounds or skin, especially deep wounds with high bacterial presence.

The spray system enables the same antimicrobial mode of action as the wound dressing while ensuring high surface area which will enable eradication of bacteria from deep and uneven wounds.

This scientific basis for this product has been evaluated scientifically and published in a peer-reviewed journal.

Coated on medical devices like catheters

Antibacterial coatings:

Short-term implantable medical devices such as urinary catheters are widely used in hospitals and nursing homes to relieve urinary retention and incontinence.

In these types of medical devices, the most common and life-threatening complication is catheter associated urinary tract infections (CAUTI), that affect over 10 million patients every year with high economic cost and patient suffering. Antimicrobial resistance has made it difficult to treat CAUTI via conventional antibiotics.

With an increasingly ageing population and rising costs to treat CAUTIs, a strong need exists for innovative anti-bacterial catheters that prevent bacterial colonisation on the catheter walls.

Amferia has early ongoing research in collaboration with Chalmers University of Technology into enabling our technology as a whole catheter or as coatings to existing catheters. The base technology, amphiphilic antimicrobial hydrogel may be developed into tough silicone like materials or can be tailored as coatings to silicone surfaces. Both these prospects are tested today as proof-of-concepts and published in scientific articles.  

Get in touch for partnership, licensing and distribution

Partnership:

Amferia is interested to engage in discussions with companies who have business interest in utilising our innovation in possible product combinations through partnership structures. Within wound care, Amferia has the possibility to offer finished or semi-finished products for commercial or distribution partnerships.

Please contact: Saba Atefyekta, Sales Director and Co-founder

Read about our patents >


Wound dressing ready for production

Production:

Amferia is working in partnership with a manufacturer to produce a high volume of Amferia wound care dressings. Amferia currently operates a clinical production site in Mölndal, Sweden, for testing and evaluating these products. Informed by those results, we are building capacity for a high volume production of wound dressings with an established partner.  

Addressing antibiotic resistance the sustainable way

Antibiotic resistance:

Over time, harmful bacteria continue to evolve. In what is rapidly becoming a health care crisis, many bacteria have already developed antibiotic resistance (ABR). Simple infections such as skin wound infections can become lethal. Today, across the world, many types of bacteria have evolved to an extent where none of our antibiotics are effective against them.

For example, Methicillin Resistant Staph. Aureus (MRSA) evolved from an ordinary bacteria. It has become what’s known as a“superbug,” resistant to many common antibiotics. A skin infection involving MRSA can develop life-threatening complications. MRSA is only one of the many superbug strains. At current rates of microbial evolution, WHO warns, drug-resistant infection may kill more people than cancer by 2050.  

The role of innovations such as Amferia’s focus on addressing antibiotic resistance through relying less of antibiotics and supplementing the same with good hygiene, education on antibiotic use and smarter antimicrobial technologies that do not increase the risk of new resistance. 

Using bioinspired materials, derived from our immune system, to kill bacteria comes with numerous advantages. These have targeted effect towards bacteria without harm to our own cells and offer potent local action at the site of an infection, with no leaching into the body or environment.

In this context, Amferia’s innovation and the wound care dressing is more than a plaster, but rather a new platform that aids and supports the mitigation of antibiotic resistance. 

Amferia presents at Brilliant Minds conference 2019, Stockholm

June 15, 2019

Amferia was honoured to pitch as one of the ‘Next Brilliant in Tech‘ at Brilliant Minds 2019 held at Stockholm between 13-15 June. With esteemed guests like President Barack Obama, Secretary John Kerry, Greta Thunberg, the conference was an enlightening and inspiring event with much hope for the future.

The Recent UN Report on Antibiotic Resistance

May 3, 2019

The United Nations appointed Interagency Coordination Group on Antimicrobial Resistance (IACG) has presented its report on Recommendations to Combat Antimicrobial Resistance (AMR). It is clear from the report that AMR is a global and complex threat that needs to be addressed with extreme urgency and with care. Consistent, coordinated and conscious actions are demanded, especially from the World Goverments, Academia, Public, Healthcare-Industry and  Agriculture. A world where bacterial infections cannot be fought efficiently is a world of perils.

Here is an excerpt from the IACG report.

“The challenges of antimicrobial resistance are complex and multifaceted, but they are not insurmountable. Implementation of the recommendations in this report will help to save millions of lives, preserve antimicrobials for generations to come and secure the future from drug-resistant diseases.

But there is no time to wait.”

-IACG Report, April 29, 2019

Do take a minute and read the summary of this important report (English, pdf 653 kb)

Amferia featured in Göteborgs-Posten

February 8, 2019

New patch from Gothenburg kills bacteria in wounds. Read to know more

Amferia wins the Swedbank Rivstart 2018

February 7, 2019

Amferia is proud to become the winners of the annual entrepreneur competition hosted by Swedbank, Rivstart. From over 1825 applications, Amferia finished on top!

Amferia wins the Venture Day 2018, hosted by Chalmers Ventures

November 28, 2018

Amferia is proud to be named winners of the annual Pitch competition hosted by Chalmers Ventures.